🟠 Moderate Evidence
A novel dual vaccine targeting both Lassa fever and rabies has demonstrated safety and immunogenicity in its first human clinical trial, researchers at the University of Maryland School of Medicine’s Center for Vaccine Development and Global Health reported. The phase 1 study, published in Nature Medicine, represents a significant step forward in addressing Lassa fever, a hemorrhagic fever endemic to West Africa for which no licensed vaccines currently exist.
Key takeaways
- First-in-human trial shows dual Lassa fever-rabies vaccine is safe and generates immune responses against both viruses
- No licensed vaccines against Lassa fever are currently available on the market
- Results published in Nature Medicine represent important progress for West African public health
Study at a Glance
| Source | Nature Medicine |
| Study type | Phase 1 clinical trial |
| Sample size | First-in-human participants |
| Population | Healthy adult volunteers |
| Institution | University of Maryland School of Medicine |
Lassa Fever: A Critical Gap in Global Vaccine Coverage
Current vaccine availability for major hemorrhagic fevers
Source: WHO Vaccine Pipeline Database, 2026 | Georgian Medical Journal News
Promising Safety and Immunogenicity Profile
The University of Maryland research team, led by the Center for Vaccine Development and Global Health, conducted the phase 1 trial to evaluate the safety, tolerability, and immune response of their novel dual vaccine platform. The study found that participants developed immune responses against both Lassa fever virus and rabies virus without significant adverse events.
“This represents an important milestone in our efforts to develop vaccines against neglected tropical diseases that disproportionately affect resource-limited settings,” the research team noted in their Nature Medicine publication. The dual-target approach offers potential advantages for deployment in regions where both diseases pose public health threats.
Addressing a Critical Global Health Gap
Lassa fever affects an estimated 100,000 to 300,000 people annually across West Africa, according to the World Health Organization. The hemorrhagic fever has a case fatality rate ranging from 1% in the general population to 15% among hospitalized patients, with higher mortality rates during pregnancy.
The absence of licensed vaccines has left populations in endemic areas vulnerable to outbreaks. Current prevention strategies rely primarily on avoiding contact with infected rodents and implementing infection control measures in healthcare settings. For more insights on emerging vaccine research, our coverage tracks the latest developments in preventive medicine.
Implications for West African Public Health
The successful completion of this first-in-human trial positions the dual vaccine for advancement to larger phase 2 studies. The Centers for Disease Control and Prevention has identified Lassa fever vaccine development as a priority for global health security, particularly given its potential for epidemic spread.
Researchers noted that the dual vaccine approach could provide logistical advantages in regions where both Lassa fever and rabies are endemic. Nigeria, Sierra Leone, Liberia, and Guinea represent priority countries for future vaccine deployment, should the candidate advance through clinical development. Our global health coverage continues to monitor vaccine equity initiatives across Sub-Saharan Africa.
The dual vaccine demonstrated safety and induced immune responses against both Lassa fever and rabies viruses in healthy adult volunteers
— University of Maryland research team (Nature Medicine, 2026)
What this means
Frequently asked questions
When might a Lassa fever vaccine become available?
This phase 1 trial represents early-stage development, with phase 2 and 3 trials still required before regulatory approval. The timeline for vaccine availability typically spans several years for successful candidates.
Why combine Lassa fever and rabies in one vaccine?
Dual vaccines can provide logistical advantages in regions where both diseases are endemic, potentially reducing costs and simplifying vaccination programs in West African countries.
How many people are affected by Lassa fever annually?
The WHO estimates 100,000 to 300,000 people are infected with Lassa fever annually across West Africa, with case fatality rates ranging from 1% to 15% depending on clinical setting.
The successful completion of this first-in-human trial marks an important step toward addressing a critical gap in global vaccine coverage. As the research advances to larger clinical studies, the dual vaccine approach could offer new hope for populations in Lassa fever-endemic regions while contributing to broader pandemic preparedness efforts.
Source: New Lassa fever vaccine shows promising results for first-in-human clinical trial
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Medically reviewed by Prof. Giorgi Pkhakadze, MD, MPH, PhD. Spotted an error? Contact the editorial team.
